• Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
ABOUT
Advertise in GAT
Contact us
Saturday, January 28, 2023
Georgia Asian Times
International Insurance of Georgia
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
  • Login
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
No Result
View All Result
Georgia Asian Times
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
Home Headline

Medicare to cover expensive cancer cell therapies

Georgia Asian Times by Georgia Asian Times
August 8, 2019
in Headline, Health
Share on FacebookShare on Twitter

Washington DC, August 8, 2019 — The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG.

CMS, which runs Medicare – the federal government’s health plan for Americans 65 and older – said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes.

The nationwide decision clears up “a lot of confusion” about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday.

The decision follows the agency’s finalization last week of a proposal to raise its maximum CAR-T payment to 65% of estimated costs from 50%. Some hospitals will also be eligible for supplemental payments in certain cases.

AD: High Museum of Atlanta

Both Gilead’s Yescarta and Novartis’ Kymriah were approved in 2017 for certain kinds of lymphoma and leukemia. But government and private health plans have balked at their high price of at least $373,000 for a one-time treatment before hospital costs, which can bring the bill for a single patient to over a million dollars.

More than half of lymphoma patients eligible for CAR-T therapy are estimated to be covered by Medicare.

The agency said it will also cover the CAR-Ts for uses not approved in their labels, as long as they are recommended by CMS-approved medical guidelines.

The novel treatments remove a type of immune system cells from each individual patient and re-engineer them to better fight certain blood cancers, keeping nearly 40% of patients alive for more than two years, according to some studies. – Reuters

Previous Post

Japan, led by less apologetic generation, stays tough in South Korea feud

Next Post

South Korea to drop Japan from its fast-track trade ‘white list’

Georgia Asian Times

Georgia Asian Times

Related Posts

You’ll likely be happier if your home follows the ‘3-30-300 rule’
Health

You’ll likely be happier if your home follows the ‘3-30-300 rule’

December 22, 2022
Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study
Health

Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study

December 14, 2022
Hospitalizations signal rising COVID-19 risk for US seniors
Health

Hospitalizations signal rising COVID-19 risk for US seniors

December 11, 2022
Low costs expected to keep Obamacare interest high
Health

Low costs expected to keep Obamacare interest high

October 31, 2022
Health

COVID-19 Updated Booster Vaccines Covered Without Cost-Sharing for Eligible Children Ages 5 to 11

October 24, 2022
Trial over Georgia’s restrictive abortion law to begin
Health

Trial over Georgia’s restrictive abortion law to begin

October 24, 2022
Next Post

South Korea to drop Japan from its fast-track trade 'white list'

Signup Free E-Newsletter

Upcoming Events

Jan 28
1:00 pm - 5:00 pm

Decatur Lunar New Year Festival

Jan 28
3:30 pm - 4:30 pm

Chinese New Year Celebration-Chamblee

Feb 18
6:00 pm - 11:00 pm

Spring Festival 2023

View Calendar
Logo

 

CONTACT US

Follow Us

MOST INFLUENTIAL

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

July 18, 2022

Video highlights of GAT 25 Most Influential Asian Americans in Georgia

July 17, 2022

2022 GAT 25 Most Influential Asian Americans in Georgia-Awards Gala

July 17, 2022

LINKS OF INTEREST

ATL Asian Film Festival

GAT on Facebook

Lunar New Year of Rabbit - GAT Special Section
  • Contact Us
  • Advertise in GAT
  • ABOUT

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

Welcome Back!

Sign In with Google
OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe

Subscribe to our newsletter for the latest
articles straight to your inbox!

    Are you sure want to unlock this post?
    Unlock left : 0
    Are you sure want to cancel subscription?